Loading
Divarasib is Roche's KRAS G12C pill, the first to beat the two approved KRAS drugs head-to-head (July 2026).
Covalent G12C inhibitor with ~5-20-fold greater potency than sotorasib/adagrasib in preclinical models; phase 1 ORR 53% in NSCLC. Krascendo 1 (vs sotorasib or adagrasib, previously treated NSCLC) met PFS and OS. Krascendo 2 tests divarasib + pembrolizumab ± chemotherapy first line. FDA orphan designation 2026; filing expected.
Covalent KRAS G12C (OFF-state) inhibitor. Connects to KRAS.
1.Divarasib slips into a pocket on KRAS.
The first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate. Source
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Divarasib" OR ABSTRACT:"Divarasib" OR TITLE:"GDC-6036" OR ABSTRACT:"GDC-6036") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Divarasib, not a curated reading list.
Shares KRAS G12C, Non-small cell lung cancer (KEGG map), KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C, KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors, KRAS.
Shares Krascendo 1, KRAS G12C, Non-small cell lung cancer (KEGG map), KRAS G12C-mutant pancreatic ductal adenocarcinoma.